CYP2D6 and breast carcinoma: Apoptosis induction of 40.12% was observed for compound 23j and it displayed good ADME characteristics including low BBB permeation, lack of CYP2D6 inhibition, and low plasma protein binding, favoring its application for the treatment of breast cancer.